Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986504 in MTAP-deleted Pancreatic Cancer
NCT07283705Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2026
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MRTX1719 in pancreatic ductal adenocarcinoma (PDAC), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2026; status: recruiting.
02
Drugs
MRTX1719
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07283705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07283705.